Biopharmaceuticals

PharmaResearch Launches REJURAN Skin Booster in Hungary

Budapest – September 22, 2026 -- South Korean biopharmaceutical company PharmaResearch officially launched its REJURAN portfolio of polynucleotide (PN)-based skin boosters in Hungary, marking its latest expansion move in Europe's aesthetic medicine market.

Symposium at Budapest museum draws 100 aesthetic medicine professionals

The launch event was held on September 14 at the Museum of Fine Arts, Budapest, marking REJURAN's first collaboration with the institution. Approximately 100 dermatologists, plastic surgeons and other aesthetic medicine specialists attended the symposium, which featured seven speakers from Korea, the Czech Republic, Slovakia and Hungary, including Korean key opinion leaders Dr. Hyun Jun Park and Dr. Kyu Ho Lee.

BoomRay Licenses Preclinical Radioligand Asset to Novartis for $900M

Suzhou – September 22, 2026 -- Boomray Pharmaceuticals Co., Ltd. has signed an exclusive global license agreement with Novartis Pharma AG for an undisclosed preclinical radioligand therapy (RLT) asset, with total deal value reaching up to USD 900 million.

Novartis secures rights to undisclosed preclinical oncology asset

Under the agreement, BoomRay will be eligible to receive an upfront payment plus development, regulatory, and sales milestone payments totaling up to USD 900 million. The Suzhou-based company will also earn royalties on future global net sales of the licensed program.

Tethis Acquires See.d Platform from MACS, Taps Everex to Scale Production

Milan – September 21, 2026 -- Tethis S.p.A. has completed the acquisition of the See.d software and engineering business unit from MACS S.r.l., gaining full control over intellectual property and engineering know-how behind its liquid biopsy platform. Alongside the transfer, Tethis signed a long-term manufacturing and supply agreement with Everex S.r.l., an Italian in-vitro diagnostic instrumentation maker, to handle production and future scale-up of the system.

Tethis consolidates full ownership of its liquid biopsy pre-analytical platform

See.d is the cornerstone of Tethis' liquid biopsy workflow, developed jointly with MACS to standardize pre-analytical blood processing. From a single blood sample, the platform generates plasma for cfDNA analysis and cytology slides preserving nucleated cells for downstream characterization, automating plasma separation, red blood cell lysis, and deposition onto Tethis' proprietary SmartBioSurface slides.

Merry Life Advances TML-6 Into 210-Patient Global Alzheimer's Phase 2

Taipei – September 21, 2026 -- Merry Life Biomedical has advanced TML-6, a Taiwan-developed oral therapy for early Alzheimer's disease, into a global Phase 2 trial spanning 20 clinical sites across Taiwan, Sweden, and the United States, targeting approximately 210 participants.

Twenty sites across three countries anchor the trial's design

The study includes nine medical centers in Taiwan, seven sites in Sweden, and four centers in the United States, with Taiwan forming the largest single group of participating sites. The randomized, double-blind, placebo-controlled trial will assign patients to TML-6 100 mg, TML-6 200 mg, or placebo, administered once daily for 52 weeks.

Akeso's Ivonescimab Wins ESMO Late-Breaking Slot for Biliary Cancer Data

Hong Kong – September 21, 2026 -- Akeso, Inc. (9926.HK) will present nearly 30 clinical studies of its bispecific antibodies at the European Society for Medical Oncology (ESMO) Congress in Madrid on October 23-27, 2026, including a Late-Breaking Abstract selected for the Presidential Symposium.

Phase III biliary tract cancer trial secures Presidential Symposium slot

Overall survival results from the Phase III HARMONi-GI1 trial, comparing ivonescimab plus chemotherapy against durvalumab plus chemotherapy as a first-line treatment for advanced biliary tract cancer, will be delivered as a late-breaking oral presentation (LBA8) on October 25 at 16:30-18:15 in Madrid. The presentation will be given by Jian Zhou of Shanghai during Presidential Symposium II.

Pharma Logistics Market to Nearly Double to $194B by 2034

Pune, India – September 21, 2026 -- The global pharmaceutical logistics market is set to nearly double from approximately $100.0 billion in 2025 to $194.0 billion by 2034, expanding at a 7.7% compound annual growth rate, according to a new report from Maximize Market Research.

Cold-chain demand for biologics and vaccines drives infrastructure investment

Growth is being fueled by rising volumes of biologics, vaccines, specialty medicines and clinical trial materials that require validated temperature control. Logistics providers are investing in refrigerated transportation, specialized cold storage warehousing and real-time temperature monitoring to protect product integrity across international drug distribution networks.

Lilly Breaks Ground on $6.5B Houston API Plant for Foundayo

Houston – – September 21, 2026 -- Eli Lilly and Company (NYSE: LLY) has broken ground on a $6.5 billion manufacturing site in Houston, Texas, that will produce active pharmaceutical ingredients for Foundayo (orforglipron), the company's first synthetic oral GLP-1 medicine for weight management.

Houston site becomes Lilly's fifth domestic API facility since 2020

The plant is one of ten U.S. manufacturing sites Lilly has announced since 2020 and the fifth dedicated to producing active pharmaceutical ingredients domestically. The investment falls under Lilly's broader $50 billion initiative to reshore medicine production in the United States and export American-made drugs globally.

PTC Therapeutics Closes ST-920 Fabry Gene Therapy Acquisition

Warren, N.J. – September 21, 2026 -- PTC Therapeutics, Inc. (NASDAQ: PTCT) has completed its acquisition of ST-920, a BLA-stage, one-time AAV gene therapy for Fabry disease, from Sangamo Therapeutics, Inc.

PTC targets Q4 2026 completion of rolling BLA submission for accelerated approval

The company confirmed that a rolling Biologics License Application submission to the FDA seeking accelerated approval of ST-920, also known as isaralgagene civaparvovec, is expected to be completed in the fourth quarter of 2026.

Made Scientific Buys 85,000 Sq. Ft. Cell Therapy Plant from National Resilience

Princeton – September 21, 2026 -- Made Scientific, Inc. has acquired an 85,000 sq. ft. clinical-to-commercial cell therapy manufacturing facility in East Norriton, Pennsylvania, from National Resilience, closing the transaction on September 18, 2026. The purchase expands the company's U.S. East Coast footprint to approximately 145,000 sq. ft. and 15 qualified GMP manufacturing suites across New Jersey and Pennsylvania.

Operational site eliminates greenfield ramp-up delays

The East Norriton facility is operational on close, with its manufacturing team having executed 145 GMP batches to date across autologous and allogeneic programs, including CAR-T and B-cell therapies. Made Scientific said sponsors can begin onboarding programs immediately, targeting 2027 clinical and commercial supply.

FDA Clears IDE for Mercy's Ovarian Cancer Blood Test Trial

Waltham, Mass. – September 21, 2026 -- The U.S. Food and Drug Administration has approved Mercy BioAnalytics' Investigational Device Exemption application for its Evident Ovarian Cancer Screening Test, clearing the way for the company's pivotal SOARA Clinical Validation Study pending Institutional Review Board sign-off.

FDA clears IDE application for Mercy's Evident Ovarian Cancer Screening Test

The approval permits Mercy to launch the prospective SOARA study -- Safety in Ovarian Cancer for Average-Risk Women, Analysis -- to evaluate the safety of the blood-based test in average-risk women. The IDE clearance does not constitute FDA approval or clearance of the Evident test itself, but authorizes the specified clinical investigation to proceed.